UBS Group began coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) in a report issued on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $21.00 target price on the stock.
Telix Pharmaceuticals Limited American Depositary Shares Stock Performance
Shares of NASDAQ TLX opened at $14.75 on Friday. Telix Pharmaceuticals Limited American Depositary Shares has a fifty-two week low of $14.75 and a fifty-two week high of $19.99.
Featured Articles
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- 3 Stocks to Consider Buying in October
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Applied Materials Market Capitulates: Now is the Time to Buy
- Business Services Stocks Investing
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
